CINCINNATI OH, November 1, 2017 – Aprecia Pharmaceuticals announced today that Dr. Timothy Tracy will serve as the company’s next Chief Executive Officer, beginning in January 2018. Dr. Tracy currently serves as the Provost for the University of Kentucky, a position he will maintain through the end of 2017.
Tracy, a Fellow with the American Association of Pharmaceutical Scientists and an expert in clinical pharmacology, brings extensive technical skills to Aprecia. He also brings to the company significant leadership competencies, having held numerous key positions at state universities, including several years spent in his current role at the University of Kentucky.
Additionally, Tracy, who earned his PhD in clinical pharmacy from Purdue University, is a registered pharmacist in the state of Ohio. He holds two patents related to drug delivery systems and has published more than 100 scientific manuscripts.
“Along with being a wonderful person and a well-respected scientist within the pharmaceutical industry, Tim Tracy has been a driving force for advancing the mission and development of the University of Kentucky,” said E. Thomas Arington, Aprecia’s Chairman. “We are excited that he will apply his extensive scientific and leadership capabilities toward the growth of Aprecia, and we look forward to the positive impact he will make across the organization.”
Aprecia’s current chief executive officer, Don Wetherhold, will stay with the company, moving to the role of Advisor to the Chairman in 2018. In this role, Wetherhold will continue to provide Aprecia support in the areas of strategic direction, business development, and product commercialization.
“Aprecia is very fortunate to retain Don Wetherhold’s services,” said Arington. “Don has led Aprecia well, and he will continue to be a key leader for the company. This new role will allow Don greater capacity to leverage his considerable industry expertise, thereby further benefitting Aprecia.”
Aprecia is the world’s first and only manufacturer of FDA-approved pharmaceutical products using three dimensional printing (3DP). The company’s ZipDose® Technology produces rapidly disintegrating orodispersible tablets designed to address patient compliance by making medicine easy to swallow and administer. Aprecia is currently positioned to expand its 3DP technology across multiple therapeutic categories. Future advancements are expected to result in specialty products that address unmet patient needs.
“Aprecia’s technology has the potential not only to transform the future of pharmaceutical manufacturing but also—and more importantly—to produce medicines that uniquely address people’s needs,” Tracy stated. “I am thrilled to be joining the Aprecia team; working with creative individuals and innovative platforms to improve patient’s lives is truly an honor.”
Aprecia, the world leader in three-dimensionally-printed pharmaceutical products, expects to use its ZipDose® Technology to transform the way people take medicine. Its first innovation, ZipDose Technology can be combined with a wide variety of active pharmaceutical ingredients to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Aprecia holds the exclusive worldwide license to the patent estate for pharmaceutical 3DP applications, and plans to license its exclusive patent protected technology to pharmaceutical partners as a means to extend product lines, expand patient reach, and protect market exclusivity for innovator’s brand products. For more information, visit www.aprecia.com.